Evidence map›Paper›PMID 40990978›Full record

ReviewVirchows Archiv : an international journal of pathology2026

Myxoid epithelioid smooth muscle tumor with a novel MEF2A::NCOA2 fusion arising in the rectum: case report and literature review.

Junko Kunieda, Kyoko Yamashita, Akito Dobashi, Yuki Togashi, Satoko Baba, Norihito Inoue, Kaoru Nakano, Akiko Chino, Shoichi Saito, Noriko Yamamoto and 2 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junko KuniedaDivision of Pathology, Institute of Science Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5563-9977
Kyoko YamashitaDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. kyoko.yamashita@jfcr.or.jp.ORCID http://orcid.org/0000-0001-6535-5951
Akito DobashiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yuki TogashiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Satoko BabaDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Norihito InoueDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kaoru NakanoDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Akiko ChinoDepartment of Lower Gastrointestinal Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Shoichi SaitoDepartment of Lower Gastrointestinal Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Noriko YamamotoDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroshi KawachiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kengo TakeuchiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science JP 22K06992Japan Society for the Promotion of Science JP 22K20767
6 · The paper itself

Abstract

Mesenchymal tumors of the gastrointestinal (GI) tract include a range of entities such as gastrointestinal stromal tumor (GIST), schwannoma, and leiomyoma; however, the genetic background of GI leiomyomas has not been elucidated. Herein, we report a case of rectal myxoid epithelioid smooth muscle tumor harboring a novel MEF2A::NCOA2 gene fusion. A 67-year-old male presented with a 16 mm tumor in the lower rectum. Pathological examination revealed a well-circumscribed lesion within the muscularis mucosae, characterized by epithelioid to spindle cells arranged in a myxoid matrix. The tumor cells displayed minimal cytological atypia and no mitotic figures. Immunohistochemistry showed strong positivity for desmin, α-SMA, h-caldesmon, and CD34, and weak DOG1 positivity. RNA sequencing revealed an in-frame MEF2A::NCOA2 fusion, which was confirmed by direct sequencing. Fluorescence in situ hybridization further verified NCOA2 rearrangement. This novel fusion gene may have been functional in this case, serving as a driver. Recently, 5 myxoid epithelioid smooth muscle tumors with MEF2D::NCOA2 gene fusion were reported in the vulvovaginal region. Given the characteristic histological and molecular findings, this case may represent a new entity in the gastrointestinal tract related to the vulvovaginal tumor, serving as a foundation for future studies.

Indexed as

Biomarkers, TumorGene FusionMEF2 Transcription FactorsNuclear Receptor Coactivator 2Rectal NeoplasmsSmooth Muscle TumorAgedHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleBiomarkers, TumorMEF2A protein, humanMEF2 Transcription FactorsNCOA2 protein, humanNuclear Receptor Coactivator 2Epithelioid leiomyomaMEF2A::NCOA2MEF family fusionMyxoid epithelioid smooth muscle tumorRectal leiomyomaRectal smooth muscle tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.